On October 24th the company has signed a framework agreement with Clinmark, an international CRO, defining the principles of comprehensive cooperation in the execution of clinical trials.

Additionaly with the framework agreement, the companies have entered into an order to conduct a phase 1/2 clinical trial in primary progressive multiple sclerosis (PPMS).

PolTREG is moving significantly closer to the start of a series of planned clinical trials using TREGs innovative cell therapy.